Eli Lilly ( LLY -1.63%) and Microsoft ( MSFT 1.20%) are two high-flying dividend stocks in the S&P 500 index. Here's why the ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE ... of risks and uncertainties relevant to Lilly's business that could cause actual results ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing back ...

(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...

Ladies and gentlemen, let’s talk about Eli Lilly. There’s something curious ... Being a one-hit wonder is a risky business model. Every novelty wears out eventually. Obesity drugs might ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily outperforming both the S&P 500 and Nasdaq Composite indexes. Much of the ...